Literature DB >> 9716578

A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans.

J P Bossavy1, C Thalamas, L Sagnard, A Barret, K Sakariassen, B Boneu, Y Cadroy.   

Abstract

No randomized study comparing the effect of combined ticlopidine and aspirin therapy versus each drug alone in reducing poststenting thrombotic complications has been performed. To compare these three antiplatelet regimens versus placebo, we conducted a double-blind randomized study using an ex vivo model of thrombosis. Sixteen healthy male volunteers were assigned to receive for 8 days the following four regimens separated by a 1-month period: aspirin 325 mg/d, ticlopidine 500 mg/d, aspirin 325 mg/d + ticlopidine 500 mg/d, and placebo. At the end of each treatment period, native nonanticoagulated blood was drawn directly from an antecubital vein over collagen- or tissue factor (TF)-coated coverslips positioned in a parallel-plate perfusion chamber at an arterial wall shear rate (2, 600 s-1 ) for 3 minutes. Thrombus, which formed on collagen in volunteers treated by placebo, were rich in platelets and poor in fibrin. As compared with placebo, aspirin and ticlopidine alone reduced platelet thrombus formation by only 29% and 15%, respectively (P > .2). In contrast, platelet thrombus formation was blocked by more than 90% in volunteers treated by aspirin + ticlopidine (P < .01 v placebo or each treatment alone). Furthermore, the effect of the drug combination therapy was significantly larger than the sum of the two active treatments (P < .05). Thrombus, which formed on TF-coated coverslips in volunteers treated by placebo, were rich in fibrin and platelets. Neither of the three antiplatelet treatments significantly inhibited fibrin deposition and platelet thrombus formation on this surface (P > .2). Thus, the present study shows that combined aspirin and ticlopidine therapy dramatically potentiates the antithrombotic effect of each drug alone, but that the antithrombotic effect of the combined treatment depends on the nature of the thrombogenic surface. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

2.  The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.

Authors:  Nicholas Pugh; Gavin E Jarvis; Annelize Koch; Kjell S Sakariassen; Bill Davis; Richard W Farndale
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

3.  Use of antiplatelet inhibitors in peripheral vascular interventions.

Authors:  S William Stavropoulos; Richard D Shlansky-Goldberg
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

4.  Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.

Authors:  Peter A Soden; Sara L Zettervall; Klaas H J Ultee; Bruce E Landon; A James O'Malley; Philip P Goodney; Randall R DeMartino; Shipra Arya; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-08-27       Impact factor: 4.268

5.  P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.

Authors:  Patrick Andre; Suzanne M Delaney; Thomas LaRocca; Diana Vincent; Francis DeGuzman; Marzena Jurek; Beverley Koller; David R Phillips; Pamela B Conley
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 6.  Clopidogrel: how good is it and how does it work?

Authors:  Richard A Santa-Cruz; Steven R Steinhubl
Journal:  Curr Cardiol Rep       Date:  2004-07       Impact factor: 2.931

Review 7.  Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.

Authors:  Mattia Galli; Francesco Franchi; Fabiana Rollini; Larisa H Cavallari; Davide Capodanno; Filippo Crea; Dominick J Angiolillo
Journal:  Expert Rev Clin Pharmacol       Date:  2021-05-26       Impact factor: 4.108

Review 8.  The impact of blood shear rate on arterial thrombus formation.

Authors:  Kjell S Sakariassen; Lars Orning; Vincent T Turitto
Journal:  Future Sci OA       Date:  2015-11-01

9.  Protease-activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model.

Authors:  Jess Berry; Matthew T Harper
Journal:  Res Pract Thromb Haemost       Date:  2022-04-11

Review 10.  De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?

Authors:  Mattia Galli; Dominick J Angiolillo
Journal:  Front Cardiovasc Med       Date:  2022-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.